News articles about Opiant Pharmaceuticals (NASDAQ:OPNT) have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the technology company an impact score of 45.1286376341615 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of equities research analysts have weighed in on OPNT shares. TheStreet raised shares of Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a report on Monday, October 16th. ValuEngine downgraded shares of Opiant Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, October 2nd.
Shares of Opiant Pharmaceuticals (NASDAQ OPNT) remained flat at $$34.50 during midday trading on Tuesday. 26,200 shares of the stock were exchanged, compared to its average volume of 35,840. Opiant Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $51.90. The company has a market capitalization of $70.31, a price-to-earnings ratio of 11.94 and a beta of -1.20.
Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Friday, October 13th. The technology company reported ($0.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.70. Opiant Pharmaceuticals had a net margin of 35.68% and a return on equity of 278.86%. The company had revenue of $3.77 million during the quarter. research analysts expect that Opiant Pharmaceuticals will post -5.12 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/11/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-opiant-pharmaceuticals-opnt-share-price.html.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.